Rothschild & Co Upgrades Abbott Laboratories to Buy, Raises Price Target to $127

Rothschild & Co has upgraded Abbott Laboratories (NYSE: ABT) from a Neutral to a Buy rating. The price target for the stock has been increased from $119 to $127.